Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes (Q37499441)

20 August 2017

1 reference

title

Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes (English)

1 reference

20 August 2017

Victoria Wright

1

0 references

Martin L. Hibberd

object named as

Martin Hibberd

series ordinal

2

0 references

Michael Levin

object named as

Michael Levin

series ordinal

3

0 references

language of work or name

English

0 references

publication date

28 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

27 Suppl 2

1 reference

20 August 2017

B90-102

1 reference

Genetic and environmental influences on premature death in adult adoptees

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Why most published research findings are false

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Secretor status, smoking and carriage of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Non-secretion of ABO antigens predisposing to infection by Neisseria meningitidis and Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

ABH secretor status, as judged by the Lewis phenotypes, in Norwegian survivors from meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Immunological Investigations of Meningococcal Disease: III. Brevity of Group C Acquisition Prior to Disease Occurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Meningococcal colonization and infection in children and their household contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Seeking wisdom in innate immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

The instructive role of innate immunity in the acquired immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Innate immunity: the virtues of a nonclonal system of recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Important role for Toll-like receptor 9 in host defense against meningococcal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Tlr4: central component of the sole mammalian LPS sensor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Toll-like receptors: how they work and what they do.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

The Lps locus: genetic regulation of host responses to bacterial lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Toll-like receptors and innate immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Host genetic determinants of Neisseria meningitidis infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Infectious diseases associated with complement deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Recurrent meningococcal infections in a patient with congenital C5 deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Complement deficiency states and meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Assessment of complement deficiency in patients with meningococcal disease in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Association between familial deficiency of mannose-binding lectin and mutations in the corresponding gene and promoter region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Association of familial deficiency of mannose-binding lectin and meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Complement. First of two parts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Complement. Second of two parts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Complement evasion by human pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Fulminant meningococcal septic shock in a boy with combined inherited properdin and protein C deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Heterozygous and homozygous factor H deficiency states in a Dutch family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

FcγRIIa and FcγRIIIb polymorphisms were not associated with meningococcal disease in Western Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Relevance of genetically determined host factors to the prognosis of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Epidemic meningococcemia and purpura fulminans with induced protein C deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Deficiency of prostacyclin production in meningococcal shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Dysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Homozygous Factor V Leiden mutation in a child with meningococcal purpura fulminans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Effect of the Factor V Leiden mutation on the severity of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

The macrophage resistance gene Lsh/Ity/Bcg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Nramp transfection transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: influence on oxidative burst and nitric oxide pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Linkage of rheumatoid arthritis to the candidate gene NRAMP1 on 2q35

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Genetic influence on cytokine production and fatal meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Genetic influence on cytokine production in meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

An interleukin-1 genotype is associated with fatal outcome of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Polymorphisms in the Interleukin-1 Gene Cluster in Children and Young Adults with Systemic Meningococcemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Variable number tandem repeat polymorphism of the interleukin-1 receptor antagonist gene in meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Genome-wide association studies are coming for human infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.05.002

1 reference

20 August 2017

1 reference

PubMed ID

19477561